Candel ($CADL) Secures $52M in Funding to Advance Revolutionary Cancer Immunotherapies

Candel Therapeutics, a pioneering clinical stage biopharmaceutical company, has announced a significant funding milestone, successfully raising $52 million to advance its innovative cancer immunotherapy initiatives. Candel is at the forefront of developing off-the-shelf multimodal biological treatments designed to generate an individualized and systemic anti-tumor immune response, offering new hope to patients battling cancer. With cutting-edge platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, Candel is diligently working to bring next-generation therapies to clinical practice. The exciting lead candidate from the HSV platform, CAN-3110, is currently undergoing an investigator-sponsored phase 1 clinical trial aimed at addressing recurrent high-grade glioma (HGG). In line with this, Candel’s enLIGHTEN™ Discovery Platform utilizes human biology and advanced analytics to innovate new viral immunotherapies targeting solid tumors. Meanwhile, CAN-2409, the flagship candidate from the adenovirus platform, is making strides in various phases of clinical trials for non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized prostate cancer. The funds raised will be strategically allocated towards accelerating these trials and enhancing research capabilities, further solidifying Candel’s commitment to transforming cancer treatment. As the company innovates at the intersection of biotechnology and patient care, they invite interested parties to learn more about their promising journey by visiting www.candeltx.com or reaching out via email at info@candeltx.com.